TXG

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date.

The global single cell sequencing market is estimated at USD 1.38 billion and is projected to expand at a 15% CAGR through 2035, driven by advances in genomics, declining sequencing costs, and wider adoption in drug discovery, diagnostics, and precision medicine. North America is expected to account for approximately 50% of the market, with academic institutions representing the largest end-user segment at 60%. Key challenges include data processing requirements, quality management, and workflow costs.

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

10x Genomics has begun commercial shipments of Atera, its next-generation spatial biology platform, with booked orders exceeding 40 instruments and demand surpassing initial 2026 expectations. The platform enables whole-transcriptome analysis with single-cell sensitivity and is gaining traction across academic, translational, and biopharma research. The global spatial transcriptomics market is projected to reach $495.2 million by 2026 with a 14.7% CAGR through 2033.